In June 2013, I gave Aegerion Pharmaceuticals (NASDAQ:AEGR) an enthusiastic write up based largely on two overlooked facts. Outdated estimates put the rate of homozygous familial [HoFH] at about one in a million. At $295,000 per patient, per year, there was reasonable concern about the adoption of Juxtapid by an extremely limited potential patient base. The first source of opportunity I highlighted, back in June, stemmed from the financial community's lack of understanding of the founder effect in isolated populations. In short, the global rate of HoFH is much higher than just one in a million. I also noted that lomitapide's impending EC marketing approval, coupled with a firm denial of mipomersen, make it the only effective treatment...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|